A Preliminary Report on the Effects of Daridorexant in Patients with Comorbid Insomnia and Substance Use Disorders

Pharmaceuticals, Год журнала: 2025, Номер 18(3), С. 378 - 378

Опубликована: Март 6, 2025

Background. Sleep disturbances are frequent in patients with substance use disorders (SUDs) and associated craving addiction relapses, leading to increased clinical severity detrimental outcomes. Daridorexant, a selective dual orexin receptor antagonist, has been approved for persistent insomnia disorder (ID), but specific insights on SUDs lacking. Methods. This observational, retrospective study investigated the effects of three-month treatment daridorexant (50 mg/day) 41 outpatients comorbid IDs SUDs. Improvement subjective sleep measures, assessed Insomnia Severity Index (ISI) total time, was primary outcome measure. Changes anxiety depression symptoms, quality life, global severity, were also through following: Hamilton Anxiety Depression Rating Scale; Five-item World Health Organization Well-Being Index; Clinical Global Impression Visual Analog Scale Craving. Results. All outcomes significantly improved throughout treatment, which generally safe well tolerated, mild transient drowsiness sluggishness reported 21.1% patients. Similar improvements observed psychopathology, craving, positive correlations found among ISI scores anxiety/depression symptoms craving. An abstinence rate (i.e., absence any use, regardless amount, treatment) 65.8% detected at endpoint. Conclusions. These preliminary findings suggest that might represent promising tool treating Identifying interventions effectively targeting good safety/tolerability profile is crucial achieve remission full functional recovery.

Язык: Английский

Insomnia Hyperarousal and Sleep-Disordered Breathing Nexus Another Pathway to Deprescribing and Tapering Off

Sleep Medicine, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский